A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Amgen Inc.0 个研究点目标入组 245 人开始时间: 2020年5月29日最近更新: 2024年2月26日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 245

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•Subjects are eligible to be included in the study only if all of the following criteria apply:
•101 Subject has provided informed consent prior to initiation of any study specific activities/procedures and/or the subject's legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent.
•111 Subjects enrolled in SC1 and SC2 comparison cohort (Ph-IIC) must provide consent to participate in the additional PK sample collection requirements.
•102 Age = 18 years at time of informed consent
•Disease status: All subjects must fulfill at least 1 of inclusion criteria
•103, 104, or 105 for eligibility.
•For Ph-IIM cohort (subjects with MRD+ ALL [phase 2]) only: Subjects will be eligible for Ph-IIM if they have B-ALL and meet the MRD criteria defined in inclusion criterion #109 below. With the exception of disease status criteria (ie, inclusion criteria #103, #104, #105, #106), Ph-IIM cohort subjects must satisfy all other inclusion criteria to be eligible.
•103 Subjects with B-precursor ALL with any of the following:
•Either Refractory (to primary induction) therapy or refractory to at least 1 salvage therapy OR
•In untreated first, second, third or greater relapse or refractory relapse:
•- First Relapse is defined achievement of first CR (CR1) during upfront therapy then relapse during or after continuation therapy
•- Primary Refractory disease is defined as the absence of CR after standard induction therapy.
•- Refractory relapse is defined as lack of CR after salvage treatment
•- Second relapse or later relapse is defined as relapse after achieving a second CR (CR2) in first or later salvage
•- Refractory to salvage is defined as no attainment of CR after salvage
•104 Relapsed or Refractory at any time after first salvage therapy
•105 Relapse at any time after allogenic HSCT.
•106 Greater than or equal to 5% blasts in the BM. (Exception: Isolated Non CNS extramedullary disease [EMD]).
•107 Eastern Cooperative Oncology Group (ECOG) Performance Status = 2.
•108 Subjects with relapse or refractory B Cell ALL Ph+ disease and that are intolerant or refractory to prior tyrosine kinase inhibitors (TKIs) are eligible.
•109 For subjects in the MRD cohorts only (cohort Ph-IIM), BMB must be <5% and =0.1%. This will replace inclusion criterion #106 for subjects in this cohort
•112 Subjects with Isolated (< 5% BMB) Non CNS Extra Medullary Disease (EMD) are eligible in phase 2 cohorts Ph-IIR and Ph-IIM only.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 180
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 65

排除标准

•Disease Related
•- Active ALL in the CNS. Presence of > 5 white blood cells (WBC) per cubic millimeter in cerebrospinal fluid (CSF) with lymphoblasts present (confirmed by CSF analysis) and or clinical signs of CNS leukemia. If CSF leukemia is present subjects will have to receive intrathecal therapy and have documented negative CSF prior to enrolling.
•Other Medical Conditions
•- History or presence of clinically relevant CNS pathology or event such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis or severe (> grade 3) CNS events including ICANS from prior CD19 CART or other T cell engager therapies.
•- Current autoimmune disease or history of autoimmune disease with potential CNS involvement.
•- Active acute or chronic graft versus host disease requiring systemic treatment with immunosuppressive medication.
•- Known hypersensitivity to blinatumomab or to any component of the product formulation.
•- Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus.
•- Symptoms and/or clinical signs and/or radiological and/or sonographic signs that indicate an acute or uncontrolled chronic infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol.
•- History of malignancy other than ALL within 3 years prior to start of protocol-specified therapy except for:
•Malignancy treated with curative intent and with no known active disease present for 3 years before enrollment and felt to be at low risk for recurrence by the treating physician.
•Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
•Adequately treated cervical carcinoma in situ without evidence of disease.
•Adequately treated breast ductal carcinoma in situ without evidence of disease.
•Prostatic intraepithelial neoplasia without evidence of prostate cancer.
•- Allogeneic HSCT within 12 weeks before the start of protocol-specified therapy
•- Cancer chemotherapy within 2 weeks before the start of protocolspecified therapy. With the exception of intrathecal chemotherapy and/or low dose maintenance therapy for example vinca alkaloids, mercaptopurine, methotrexate, or hydroxyurea (any low dose chemotherapy as stated above must be discontinued before starting prephase) or pre-phase chemotherapy and/or dexamethasone.
•- Immunotherapy (eg, rituximab, alemtuzumab) within 4 weeks before start of protocol-specified therapy. Prior failed CD19 directed therapy such as prior blinatumomab or CD19 CAR T cells will be allowed (with demonstrated continued CD19+ expression), if treatment ended > 4 weeks prior to start of protocol therapy. and no prior CNS complications (see exclusion criteria 202).
•Prior/Concurrent Clinical Study Experience
•- Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study. Other investigational studies are not permitted while participating in this study.
•Diagnostic Assessments
•- Abnormal screening laboratory values as defined below:
•Total bilirubin >3.0 mg/dL prior to start of treatment (unless related to Gilbert's or Meulengracht disease) Estimated Creatinine clearance < 60 mL/min
•Other Exclusions
•- Female subject is pregnant or breastfeeding or planning t

研究者

发起方

Amgen Inc.

相似试验

进行中（未招募）

1 期

A phase 1/2 study of subcutaneous blinatumomab administration in adults with R/R B-AAdults with relapsed or refractory B-precursor ALL (R/R B-ALL)MedDRA version: 21.0Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063621Term: Acute lymphoblastic leukaemia recurrentSystem Organ Class: 100000004864

EUCTR2019-004780-52-ATAmgen130

招募中

1 期

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) PatientsB Cell Precursor Acute Lymphoblastic Leukemia

JPRN-jRCT2031230003Murakami Naoko130

招募中

1 期

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864

EUCTR2021-006038-37-GRTakeda Development Center Americas, Inc.286

进行中（未招募）

1 期

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma

EUCTR2021-006038-37-FRTakeda Development Center Americas, Inc.336

进行中（未招募）

1 期

EUCTR2019-004780-52-NLAmgen Inc.245